Floatz logo

Nivolumab

Breast Adenocarcinoma

Mayo Clinicmonoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

24 Active assets in the Breast Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3BB
Letrozole
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 4BB
TRASTUZUMAB
Academic and Community Cancer Research United
Phase 3BB
Inno-206
Virginia Commonwealth University
Phase 3BB
Carboplatin
Genmab
Phase 3BB

View all 50 →

Same molecule, other indications

Nivolumab is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
renal carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →